MONTREAL, Dec. 2, 2021 /CNW Telbec/ - Lumiera
Health Inc. (TSXV: NHP) (the "Company" or
"Lumiera "), a company specializing in the development
and commercialization of natural health products, is pleased to
provide an update to announce that the new corporate strategy and
plans that were put in place Q1-Q3 2021 have been successful.
Lumiera's fiscal Q4 was a record quarter with sales +30% vs Q4
2020, highlighted by November which was a record sale month, +59.3%
over November 2020.
The increase in the Company's sales and the accelerated quarter
over quarter growth was driven by the success of expanded
distribution, new digital and retail marketing campaigns, and the
successful performance of a new sales and in-store training team
put in place earlier in the year.
"2021 has been a foundation building year; I am really proud of
the team - we developed new strategies and plans, we pulled the
business apart, eliminated waste and refocused the team and
resources behind those strategies to drive growth of our priority
brands and products in both online and retail channels." says
Carlos Ponce, CEO of Lumiera Health.
"After a challenging front half of the year we are happy to finish
the year with sales of +10% and to see that the positive initial
results in our Q4 sales is outstanding. We are looking
forward to keep building momentum for a great 2022 and beyond."
Management will continue executing its plan for growth and
expects to see the upward sales trends continue for the foreseeable
future.
Audited financial statements will be released on or before
March 31, 2022.
About Lumiera Health
Lumiera specializes in the development and commercialization of
consumer products for the natural health industry. The Company
sells herbal tonics and natural supplements through its Holizen
Laboratories division, with a diverse portfolio including a line of
innovative sleep aids. The Company is also developing and
commercializing a unique range of products acting on the
endocannabinoid system and offering novel solutions for the
treatment of acute and chronic pain. A pioneer in the natural
health innovation space, the Lumiera brand is rooted in the core
values of science, nature and compassion. Our goal is to make
people's lives better by developing natural health and wellness
products that are effective, safe and trustworthy.
For more information visit: www.lumiera.ca.
Neither the TSX Venture Exchange nor its Regulation Services
Provider (as that term is defined in the policies of the TSX
Venture Exchange) accepts responsibility for the adequacy or
accuracy of this release.
Forward-looking information
Certain statements contained in this press release constitute
"forward-looking information" as such term is defined in applicable
Canadian securities legislation. The words "may", "would", "could",
"should", "potential", "will", "seek", "intend", "plan",
"anticipate", "believe", "estimate", "expect" and similar
expressions indicate such "forward-looking
information" as they relate to Lumiera. All statements other
than statements of historical fact may be forward-looking
information. Such statements reflect Lumiera' current views and
intentions with respect to future events, and current information
available to Lumiera, and are subject to certain risks,
uncertainties and assumptions. Such risks and uncertainties
include, among others, the risk factors included in Lumiera' annual
management's discussion and analysis for the year
ended November 30, 2020,
which is available under the issuer's SEDAR profile
at www.sedar.com. Material factors or assumptions
were applied in providing forward-looking information. Many factors
could cause the actual results, performance or achievements that
may be expressed or implied by such forward-looking information to
vary from those described herein should one or more of these risks
or uncertainties materialize. Should any factor affect Lumiera in
an unexpected manner, or should assumptions underlying the
forward-looking information prove incorrect, the actual results or
events may differ materially from the results or events predicted.
Any such forward-looking information is expressly qualified in its
entirety by this cautionary statement. Moreover, Lumiera does not
assume responsibility for the accuracy or completeness of such
forward-looking information. The forward-looking information
included in this press release is made as of the date of this press
release and Lumiera undertakes no obligation to publicly update or
revise any forward-looking information, other than as required by
applicable law.
SOURCE Lumiera Health Inc.